Open AccessSynthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?
Author(s) -
Mary J. Feigman,
Marcos M. Pires
Publication year - 2018
Publication title -
acs infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.7b00261
Subject(s) - battle , antibiotics , penicillin , immunotherapy , antibiotic resistance , intensive care medicine , medicine , human health , biology , immunology , history , microbiology and biotechnology , environmental health , immune system , archaeology
Drug resistance to our current stock of antibiotics is projected to increase to levels that threaten our ability to reduce and eliminate bacterial infections, which is now considered one of the primary health care crises of the 21st century. Traditional antibiotic agents (e.g., penicillin) paved the way for massive advances in human health, but we need novel strategies to maintain the upper hand in the battle against pathogenic bacteria. Nontraditional strategies, such as targeted immunotherapies, could prove fruitful in complementing our antibiotic arsenal.